Updates and news related to prostate cancer:
Hormone therapies for advanced prostate cancer have greatly prolonged the lives of patients
Enzalutamide has previously been FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRCP) and non-metastatic castration-resistant prostate cancer (nmCRPC).
A new pilot study concludes that at-home urine tests could make prostate cancer diagnosis shorter, simpler, and possibly even more accurate.
After treatment, 65 percent of men in study had no signs of cancer after one year.
By Radiological Society of North America, December 2, 2019
The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the American Society of Clinical Oncology.
Some men are more likely to be diagnosed with prostate cancer depending on two factors, according to research presented at the 2019 National Cancer Research Institute Conference.
An October 1, 2019 article from the Prostate Cancer Foundation
New Precision Medical Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer
Phase 3 clinical trial results demonstrate significant efficacy of the PARP-inhibitor for olaparib in advanced prostate cancer patients with specific tumor mutations
Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.